Fluconazole

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Fluconazole

Examples of brand names: Diflucan [DE]

ATC code: J02AC01

Main use (for orientation): Fungal infections

Documented research summary

Existing human pharmacokinetics establish moderate CBD and product-dependent THC/11-OH-THC changes with fluconazole; do not describe this as an increase in fluconazole concentrations. PBPK supports modelling, not a new evidence category.

Uncertainties and limitations

Oral tablet/suspension and intravenous pharmacokinetics are comparable in the label; cannabis studies are product-specific.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD + Δ9-THC (nabiximols) – clinically investigated

Finding ID: B0046

Type of result: Positive finding / indication

Observation: THC AUC +32%; 11-OH-THC AUC approximately 2.5-fold; CBD AUC not significantly changed.

Mechanism: CYP2C9 inhibition

Study type: Human pharmacokinetics according to product information

Context studied: Sativex 4 sprays; fluconazole 200 mg; n not reported.

Clinical interpretation: Possible

Limitations and uncertainties: Relevance not fully resolved.

Original sources for this finding: Sativex Oromucosal Spray – Summary of Product Characteristics [CL19]

CBD – clinically studied

Finding ID: B0085

Type of result: Positive finding / indication

Observation: CBD AUC +22%, Cmax +24%; 7-OH-CBD reduced.

Mechanism: CYP2C19 inhibition investigated

Study type: Phase I data in a study overview

Context studied: Pharmaceutical CBD, healthy participants.

Clinical interpretation: Small in the regimen investigated

Limitations and uncertainties: Differs from the nabiximols/THC context.

Original sources for this finding: Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs [CL24]; EPIDIOLEX (cannabidiol) oral solution – Prescribing Information, revised 6/2025 [CL02]

References and access status

[V2_LABEL_D0307] DIFLUCAN (FLUCONAZOLE) TABLET DIFLUCAN (FLUCONAZOLE) POWDER, FOR SUSPENSION [ROERIG]

Original source / bibliographic reference

Authors: Roerig

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL19] Sativex Oromucosal Spray – Summary of Product Characteristics

Original source / bibliographic reference

Authors: SVX Therapeutics Limited

Year: 2026

Source type: Regulatory product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL24] Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

Original source / bibliographic reference

Authors: Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G

Year: 2020

Source type: Study overview including manufacturer data; PubMed: review

DOI: 10.1111/epi.16674

PMID: 32918835

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[BMED36540909] Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling.

Original source / bibliographic reference

Authors: Yeung CHT, Beers JL, Jackson KD, Edginton AN.

Year: 2023

Source type: Publication; title and abstract reviewed

DOI: 10.1002/psp4.12908

PMID: 36540909

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[CL02] EPIDIOLEX (cannabidiol) oral solution – Prescribing Information, revised 6/2025

Original source / bibliographic reference

Authors: FDA / Jazz Pharmaceuticals

Year: 2025

Source type: Regulatory product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility